Book a Meeting

Non-Fucosylated Anti-Human FGF23 (KRN23) Therapeutic Antibody (CAT#: BioBet-884ZP) Datasheet

Target
FGF23
Isotype
IgG
Description
ADCC-Enhanced anti-FGF23 (KRN23) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Hypophosphatemic disease
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced FGF23 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
FGF23
Full Name
fibroblast growth factor 23
Background
This gene encodes a member of the fibroblast growth factor family of proteins, which possess broad mitogenic and cell survival activities and are involved in a variety of biological processes. The product of this gene regulates phosphate homeostasis and transport in the kidney. The full-length, functional protein may be deactivated via cleavage into N-terminal and C-terminal chains. Mutation of this cleavage site causes autosomal dominant hypophosphatemic rickets (ADHR). Mutations in this gene are also associated with hyperphosphatemic familial tumoral calcinosis (HFTC).
Alternative Names
FGF23; fibroblast growth factor 23; ADHR; FGFN; HYPF; HPDR2; PHPTC; phosphatonin; tumor-derived hypophosphatemia inducing factor; KRN23, KRN-23, UX023
Gene ID
8074
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with FGF23 include Hypophosphatemic Rickets, Autosomal Dominant and Tumoral Calcinosis, Hyperphosphatemic, Familial, 2.
Related Pathways
Its related pathways are RET signaling and Signaling by FGFR2 in disease.
Function
Regulator of phosphate homeostasis. Inhibit renal tubular phosphate transport by reducing the level of SLC34A1. Up-regulate the expression of EGR1 in the presence of KL (via similarity). Acts directly on the parathyroid glands, reducing parathyroid secretion (similar). Vitamin d metabolism regulator. Negatively regulate osteoblast differentiation and matrix mineralization.
Field of research
Cancer antibody; Controls and Markers antibody; Developmental Biology antibody; Signaling Transduction antibody
Post-translational modifications
Following secretion this protein is inactivated by cleavage into a N-terminal fragment and a C-terminal fragment. The processing is effected by proprotein convertases. O-glycosylated by GALT3. Glycosylation is necessary for secretion; it blocks processing by proprotein convertases when the O-glycan is alpha 2,6-sialylated. Competition between proprotein convertase cleavage and block of cleavage by O-glycosylation determines the level of secreted active FGF23.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
KRN23
Host
Human
Species Reactivity
Human
Description
KRN23 is a recombinant fully human monoclonal antibody against FGF23, in pediatric subjects with X-linked hypophosphatemia (XLH).
Indication
Hypophosphatemic disease

Hypophosphatemic disease

Related Products

BetterBet™ Anti-FGF23 On-Target Antibody (CAT#: AES-0622-ZP712)
Highly Galactosylated Anti-FGF23 (Burosumab) Antibody (CAT#: BioBet-GA-013ZP)
BetterBet™ Anti-FGF23 Half-Life Extended Antibody (CAT#: AES-0622-ZP1040)
Non-fucosylated Anti-Human FGF23 (Burosumab) Therapeutic Antibody (CAT#: BioBet-013ZP)
BetterBet™ Anti-FGF23 FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP384)
BetterBet™ Anti-FGF23 Recycling Antibody (CAT#: AES-0622-ZP56)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany